Reuters logo
BRIEF-Corbus Pharma's inflammatory disease drug succeeds mid-stage study
2017年10月19日 / 下午3点27分 / 1 个月前

BRIEF-Corbus Pharma's inflammatory disease drug succeeds mid-stage study

Oct 19 (Reuters) - Corbus Pharmaceuticals Holdings Inc

* Corbus Pharmaceuticals reports positive topline results from phase 2 study in rare autoimmune disease dermatomyositis

* Corbus Pharmaceuticals Holdings Inc - ‍Anabasum was well tolerated with no severe or serious side effects associated with drug​

* Corbus Pharmaceuticals Holdings Inc - ‍Anabasum also outperformed placebo in multiple secondary efficacy outcomes studied​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below